LTRN — Lantern Pharma Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1763950 ·
Last close
$1.22
Market Cap
$15.60M
52W High
$4.70
52W Low
$1.11
ADV30
206,543
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,508,090 | -7,072,124 | 8,602,349 | 6,660,170 | 11,819,601 |
| Mar 2026 | 0 | — | -3,405,247 | -3,329,171 | 7,223,067 | 4,917,796 | 3,777,366 |
| Dec 2025 | 0 | — | -4,202,762 | -4,074,217 | 11,035,811 | 4,422,838 | 4,501,587 |
| Sep 2025 | 0 | — | -4,349,800 | -4,177,423 | 13,626,810 | 8,389,486 | 4,039,972 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,073,997
Investing CF
$12,067,742
Financing CF
$1,498,240
CapEx
$-4,798
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.51
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-96,474,226
Inventory
—
Receivables
—
ST Investments
$1,405,057
EBIT TTM
$-16,609,709
Pretax Income TTM
$-15,911,826
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -17,978,494 | -17,119,438 | 11,035,811 | 4,501,587 | 6,534,224 | -15,676,980 |
| Dec 2024 | 0 | -22,216,437 | -20,781,213 | 25,571,792 | 4,384,018 | 21,187,774 | -17,813,201 |
| Dec 2023 | 0 | -17,877,570 | -15,961,534 | 43,647,616 | 2,739,682 | 40,907,934 | -14,346,548 |
| Dec 2022 | 0 | -14,432,753 | -14,259,946 | 58,836,321 | 2,798,297 | 56,038,024 | -12,767,492 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.02
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $1.23 · call volume: 120 · put volume: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CMMB | Chemomab Therapeutics Ltd. | $15.83M | $2.16 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $15.90M | $0.58 | — |
| DARE | Dare Bioscience, Inc. | $15.26M | $0.78 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $16.33M | $0.68 | — |
| ALLR | Allarity Therapeutics, Inc. | $16.39M | $1.03 | — |
News headlines (Yahoo Finance, 1h cache)
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
2026-09-23 11:45 · Yahoo
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
2026-09-19 15:45 · Yahoo
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
2026-09-17 12:20 · Yahoo
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
2026-09-05 14:50 · Yahoo
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
2026-08-21 12:28 · Yahoo
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ...
2026-08-20 01:03 · Yahoo
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 11:30 · Yahoo
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
2026-08-07 12:00 · Yahoo
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
2026-08-03 11:30 · Yahoo
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
2026-07-28 11:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.